OTCMIBOGF
Market cap4mUSD
Jan 13, Last price
0.02USD
1D
0.00%
1Q
10.70%
IPO
-80.18%
Name
Universal Ibogaine Inc
Chart & Performance
P/E
—
P/S
5.75
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
1m
Net income
-10m
L+171.41%
CFO
-4m
L+33.34%
Profile
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. It undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. The company is headquartered in Calgary, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2022‑07 | 2021‑07 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||
Revenues | 1,071 | |||||
Cost of revenue | 4,977 | |||||
Unusual Expense (Income) | ||||||
NOPBT | (3,906) | |||||
NOPBT Margin | ||||||
Operating Taxes | (60) | |||||
Tax Rate | ||||||
NOPAT | (3,846) | |||||
Net income | (10,496) 171.41% | |||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 6,074 | |||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | 1,738 | |||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | 1,012 | |||||
| Cash flow | ||||||
Cash from operating activities | (4,333) | |||||
CAPEX | (96) | |||||
Cash from investing activities | (2,089) | |||||
Cash from financing activities | 7,006 | |||||
FCF | (6,482) | |||||
| Balance | ||||||
Cash | 726 | |||||
Long term investments | ||||||
Excess cash | 673 | |||||
Stockholders' equity | 3,943 | |||||
Invested Capital | 5,008 | |||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 185,637 | |||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (3,640) | |||||
EV/EBITDA | ||||||
Interest | 68 | |||||
Interest/NOPBT | ||||||